|
Article Cited by others ORIGINAL ARTICLE
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
Assadi Majid, Rezaei Samira, Jafari Esmail, Rekabpour Seyed Javad, Ravanbod Mohammad Reza, Zohrabi Farshad, Amini AbdulLatif, Keshmiri Saeid, Dadgar Habibollah, Ahmadzadehfar Hojjat
Year : 2020| Volume: 19| Issue : 1 | Page no: 15-20 | This article has been cited by | | 1 |
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study |
|
| | Milka Marinova,Reza Alamdar,Hojjat Ahmadzadehfar,Markus Essler,Ulrike Attenberger,Martin Mücke,Rupert Conrad | | | Nuklearmedizin. 2020; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis |
|
| | Finn Edler von Eyben,Glenn Bauman,Rie von Eyben,Kambiz Rahbar,Cigdem Soydal,Alexander R. Haug,Irene Virgolini,Harshad Kulkarni,Richard Baum,Giovanni Paganelli | | | International Journal of Molecular Sciences. 2020; 21(23): 9054 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
|
|
Users Online: 169 
